This research study will evaluate safety and how well the study drug, nintedanib improve
symptoms in participants with myositis associated interstitial lung disease (MA-ILD).
Interstitial lung disease is a disorder caused by the abnormal accumulation of cells
structures between air sacs of the lungs resulting in thickening, stiffness and scarring of
the tissues of the lung.
This study will enroll a total of 134 participants across 15 clinical sites located in the
United States. A subset of participants will be enrolled remotely via telemedicine utilizing
certified mobile home research nurses and various remote monitoring devices.
The research visits may include a physical exam, vital signs (such as blood pressure, heart
rate, etc.), pulmonary function tests (PFT and/or home spirometry), Computerized Tomography
(or CT) scans of the chest, blood draws, wearing a physical activity monitor and completing
questionnaires. Some of these events may be done at home, at a local facility or remotely
(via telemedicine).